Doha Omar Alghamdi

Dr. Doha Omar Alghamdi

Pharmacology, King Abdulaziz University, Jeddah, Makkah al Mukarramah, Saudi Arabia
orcid
PhD pharmacology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Pakistan Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Hossam AbdallahHossam Abdallah
Hossam Abdallah
Doha Omar AlghamdiDoha Omar Alghamdi
Doha Omar Alghamdi
MAMaab Siddiq Al-Salem
Maab Siddiq Al-Salem
MAMaryam Alattas
Maryam Alattas
HEHany Mohamed El-Bassossy
Hany Mohamed El-Bassossy
Essam Abdel-SattarEssam Abdel-Sattar
Essam Abdel-Sattar
Diabetes is a disease characterized by elevated uncontrolled glucose level

28 October 2021 in Journal of Pharmaceutical Research International
Verified
Journal Article
Closed access
PDF file
Doha Omar AlghamdiDoha Omar Alghamdi
Doha Omar Alghamdi
HKHala S. Abdel Kawy
Hala S. Abdel Kawy
ZDZoheir A. Damanhouri
Zoheir A. Damanhouri
Pulmonary fibrosis is a disease of the lower respiratory system. It might be as Idiopathic fibrosis which is obscure reason for disease or might be as an optional impact from different causes, for example, the environmental causes, for example, toxins and smoking, some connective tissue illnesses., infection diseases, for example, tuberculosis (TB) and corona virus, a few medications, for example, bleomycin, methotrexate, and radiation treatment. Glucocorticoid are used for treating inflammatory and immune diseases, like asthma, but interstitial lung disease, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) at some stage, may become resistant to corticosteroid treatment. Glucocorticoids inhibit inflammation by many mechanisms. The oxidative stress leads to significantly decrease in activity and expression of Histone deacetylase 2 (HDAC-2) which causes resistant to the action of glucocorticoid. However, the dissociated glucocorticoids have been developed to decrease side effects, the dissociated glucocorticoid receptor agonists (DIGRAs) are a class of experimental drugs designed to share many of the desirable anti-inflammatory, immunosuppressive, or anticancer properties of classical glucocorticoid drugs with fewer side effects, but it is so difficult to dissociate anti-inflammatory effects from adverse effects. Patients with glucocorticoid resistance must use alternative anti-inflammatory treatments as well as drugs that may reverse the molecular mechanism of glucocorticoid resistant. Objective: This paper is to review the corticosteroid resistant pulmonary fibrosis and how overcome this resistance. The data was collected from December 2020 to September 2021.

22 May 2023 in Journal of Umm Al-Qura University for Medical Science
Verified
Journal Article
Closed access
Doha Omar AlghamdiDoha Omar Alghamdi
Doha Omar Alghamdi
HEHala Eweis
Hala Eweis
ZDZoheir Damanhouri
Zoheir Damanhouri

23 August 2023
Verified
Book Chapter
Open access
PDF file
Doha Omar AlghamdiDoha Omar Alghamdi
Doha Omar Alghamdi
AAAbdulrahman Alghamdi
Abdulrahman Alghamdi
Glucocorticoids, the main anti-inflammatory medication, are useful for the treatment of many diseases such as inflammation, respiratory diseases, malignancies, etc., but unfortunately, glucocorticoids cannot inhibit inflammation by various mechanisms. The definition of glucocorticoid resistance is loss of efficacy or reduced sensitization over time and increases due to chronic inflammation. It is affecting 30% of glucocorticoid-treated patients. It shows an essential restriction in the treatment of chronic inflammation and malignancies diseases and can be due to the impairment of various mechanisms along the signaling pathway of glucocorticoids. However, glucocorticoids dissociation has been improved to reduce the SE, DIGRAs “receptor of glucocorticoid dissociation agonists” are a group of trial drugs developed to share various wanted as an anti-inflammatory, suppress immunity, or properties of anti-malignancies of traditional steroids medications with lesser adverse events, but it is so hard to dissociate anti-inflammatory effects from adverse effects. Cases with glucocorticoid unresponsive should use other medications with similar mechanisms in inflammation as well as drugs that may change the molecular mechanism of resistance to glucocorticoid. Here, we discuss the evidence that exists for the hypothesis that individual glucocorticoid resistance underlies the problem.

13 September 2021 in Research Square
Verified
Preprint
Open access
PDF file
Doha Omar AlghamdiDoha Omar Alghamdi
Doha Omar Alghamdi
HKHala S Abdel Kawy
Hala S Abdel Kawy
ZDZhair A Damanhouri
Zhair A Damanhouri
Background: Corticosteroid resistance pulmonary fibrosis is a major health problem. This study aimed to determine the effectiveness of nintedanib on corticosteroid resistance pulmonary fibrosis induced by bleomycin in mice. Methods: The mice were divided into five groups 12 mice each. control group, BLM group received single dose of bleomycin (BLM), BLM+MP group received BLM and methylprednisolone (MP), BLM+NIN group received BLM and nintedanib(NIN) and BLM + NIN + MP group. The lung tissues were obtained for biochemical analysis, gene expression and histopathological examination on day 7 and day 28. Results: after 7 days, both NIN groups showed a significant decrease in the levels of interleukin-2, interleukin-4, interferon-gamma, lung tumor necrosis factor-alpha, Malondialdehyde and lung water content with a significant increase in the Glutathione level in lung tissues compared to MP group. After 28 days, both NIN groups showed a significant reduction in hydroxyproline, and Trans-forming Growth Factor beta lung tissues contents compared to MP group, and they showed a positive effect on the expression of β 3 &β6 integrins compared to the negative effect of MP group. Histopathologically, both NIN groups showed significant improvement compared to MP group by H&E and Masson’s trichrome stains. Immunohistochemical staining revealed negative BCL-2 expression in the cytoplasm of bronchiolar epithelium in both NIN groups after 7 and 28 days of treatment. Lung tissue morphometric studies showed significant improvement of pathological changes induced by BLM in both NIN groups. Conclusion: Altogether, our data indicates that nintedanib overcame corticosteroid resistance pulmonary fibrosis induced by bleomycin.

19 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
Doha Omar AlghamdiDoha Omar Alghamdi
Doha Omar Alghamdi
HEHala Eweis
Hala Eweis
ZDZoheir Damanhouri
Zoheir Damanhouri
Background Corticosteroid resistance pulmonary fibrosis is a major health problem. This study aimed to determine the effectiveness of nintedanib on corticosteroid resistance pulmonary fibrosis induced by bleomycin in mice. Methods The mice were divided into five groups 12 mice each. control group, BLM group received single dose of bleomycin (BLM), BLM + MP group received BLM and methylprednisolone (MP), BLM + NIN group received BLM and nintedanib(NIN) and BLM + NIN + MP group. The lung tissues were obtained for biochemical analysis, gene expression and histopathological examination on day 7 and day 28. Results after 7 days, both NIN groups showed a significant decrease in the levels of interleukin-2, interleukin-4, interferon-gamma, lung tumor necrosis factor-alpha, Malondialdehyde and lung water content with a significant increase in the Glutathione content in lung tissues compared to MP group. After 28 days, both NIN groups showed a significant reduction in hydroxyproline, and Trans-forming Growth Factor beta lung tissues contents compared to MP group, and they showed a positive effect on the expression of β 3 &β6 integrins compared to the negative effect of MP group. Histopathologically, both NIN groups showed significant improvement compared to MP group by H&E and Masson’s trichrome stains. Immunohistochemical staining revealed negative BCL-2 expression in the cytoplasm of bronchiolar epithelium in both NIN groups after 7 and 28 days of treatment. Lung tissue morphometric studies showed significant improvement of pathological changes induced by BLM in both NIN groups. Conclusions Altogether, our data indicates that nintedanib overcame corticosteroid resistance pulmonary fibrosis induced by bleomycin.